Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04372108 · ClinicalTrials.gov registry record
A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis
A clinical trial of Crohn Disease and Colitis, Ulcerative, sponsored by Janssen Scientific Affairs.
- Recruiting
- Registry status
- 1,056
- Enrollment target
- 1
- Study location
NCT04372108 is a study of Crohn Disease and Colitis, Ulcerative that is actively recruiting participants, run by Janssen Scientific Affairs. The registered enrollment target is 1,056 participants, above the 191-participant average among 71 other Crohn Disease trials with a reported enrollment target (453% higher). The trial reports 1 study location across 1 state.
The verdict
NCT04372108, a study of Crohn Disease and Colitis, Ulcerative, is actively recruiting participants, sponsored by Janssen Scientific Affairs.
- RECRUITING
- Registry status
- 1,056 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG Other Biologic Therapies
Study Locations (1)
Virginia
- NMCP - Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,056 participants |
| Start Date | 2021-06-24 |
| Est. Completion | 2030-08-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04372108
The ClinicalTrials.gov registry entry for NCT04372108 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 1,056 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 191-participant average among 71 other Crohn Disease trials with a reported enrollment target (453% higher). The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which Ustekinumab is the first listed.
NCT04372108 reports 1 study location spanning 1 distinct geographic area - top geographies include Virginia.
Frequently Asked Questions
What is clinical trial NCT04372108 about?
NCT04372108 is a clinical study titled "A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis". The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).
What is the current status of trial NCT04372108?
This trial is currently recruiting. The enrollment target is 1,056 participants. The study started on 2021-06-24. Estimated completion is 2030-08-30.
What conditions does trial NCT04372108 study?
This clinical trial studies the following conditions: Crohn Disease, Colitis, Ulcerative.
What interventions are being tested in trial NCT04372108?
The interventions under investigation include: Ustekinumab (DRUG), Other Biologic Therapies (DRUG).
Who is sponsoring clinical trial NCT04372108?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04372108 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
RECRUITING · NA
-
Low Dose IL-2 for the Treatment of Crohn's Disease
RECRUITING · Phase 1
-
Registry and Biorepository for IBD in Central Texas
RECRUITING
-
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.